Allogeneic stem cell transplantation (ASCT) is a complex medical procedure for some patients with hematologic malignancies. Most ASCTs occur at academic centers where either medical residents (house staff [HS]) or advanced practice providers (APPs) provide daily care. As a result of increasing work-hour regulations, APPs have assumed greater responsibilities, including those traditionally held by HS. In this study we evaluate ASCT patient outcomes by inpatient provider service. A retrospective, single-center chart review of ASCT patients was performed. ASCT patients admitted to an HS service from May 2011 to May 2012 (N ¼ 86) were compared with ASCT patients admitted to a newly formed APP service from October 2012 to October 2013 (N ¼ 81). As part of a secondary sensitivity analysis, we compared ASCT patients on the APP service to a subset of ASCT patients admitted to the HS service also from October 2012 to October 2013 (n ¼ 27). Our primary outcomes were 100-day survival and relapse-free survival rates. Additional outcomes included length of stay (LOS), inpatient complications, and ordering behavior. Our primary pre-and post-analyses found no differences in 100-day overall survival and 100-day relapse-free survival rate between the services. The rate of pneumonia was lower on the APP service (15% versus 28%, P ¼ .04), with no significant differences in other infectious complications. HS ordered more blood cultures (6.7 versus 4.2, P ¼ .03) per patient than the APP service. There was no difference in LOS, readmission rates, or inpatient mortality. With regards to our secondary sensitivity analysis, no differences were found in 100-day overall survival and 100-day relapse-free survival rates between the services. There was a decreased LOS on the APP service (29.4 versus 37.2 days, P ¼ .01). HS ordered more blood cultures (9.3 versus 4.2, P < .01) and more radiological films (8.1 versus 5.2, P ¼ .05) per patient than the APP service. This increased ordering and LOS was associated with an increase in mean hospital charges on the HS service (P ¼ .04). ASCT patients on an APP service had similar 100-day outcomes as those on the HS service. In the setting of limited resources, APPs are potential alternative providers for complex transplant inpatients. Ó
INTRODUCTION
Allogeneic stem cell transplantation (ASCT) is a potentially curative, high-risk procedure for the treatment of select patients with hematologic malignancies [1] [2] [3] . The care of these patients most often occurs at tertiary academic referral centers where medical residents (house staff [HS] ) or nurse practitioners and physician assistants (advanced practice providers [APPs] ) provide the day-to-day care under the supervision of an attending physician [4] . Over the last 2 decades there has been an increase in both the number and complexity of ASCTs performed each year. From 1994 to 2005 the overall number of ASCTs increased by 45%, with an increased proportion of higher risk transplants using unrelated donors and cord blood [5] .
Simultaneously, along with the increased number and complexity of ASCTs there has been a change in medical Biology of Blood and Marrow Transplantation j o u r n a l h o m e p a g e : w w w . b b m t . o r g education work-hour rules necessitating an adjustment in the roles of clinicians providing the daily care for these patients. First in 2003 and again in 2011, the American Council for Graduate Medical Education implemented new regulations limiting the number of hours that HS can work in the hospital [6, 7] . These changes in the setting of increasing demand for oncological services [8, 9] has led to adaptation of new care models using alternative care providers such as APPs [9] [10] [11] [12] . Specifically in the care of ASCT patients, a recent study demonstrated that APPs were a part of the inpatient team in 77% of the surveyed institutions, whereas only 24% of these institutions used HS [4] . Despite this widespread usage of APPs, little data evaluate the effects of transitioning from HS to APPs in the setting of ASCT.
The role of APPs in the inpatient care of patients has been validated in other settings, including general medicine wards [13, 14] , the intensive care unit (ICU) [15] , trauma service [16] , and most recently inpatient oncology units [17] . These studies have all found similar overall survival irrespective of the type of inpatient provider with potential clinical benefits associated with the implementation of APPs, such as decreased length of stay (LOS). In contrast to these previous studies, ASCT patients represent a unique, highly complex population that is admitted for a specific procedure with significant morbidity and mortality risk [2, 3] . In this study we compare patient outcomes on a newly developed APP service compared with a traditional HS service in an inpatient ASCT population.
METHODS

Study Design
A retrospective chart review of ASCT patients admitted to the Hospital of the University of Pennsylvania was performed.
Study Site and Patient Population
We evaluated all patients admitted to Hospital of the University of Pennsylvania for ASCT from May 2011 to October 2013. Before July 2012 all ASCT patients were admitted to an HS service. Starting July 2012 all ASCT patients were to be admitted to a newly developed APP service. Patients admitted from June 2012 to September 2012 were excluded from analysis due to transition and crossover that occurred during the initial months of the new service ( Figure 1 ). This study was reviewed and approved by the institutional review board at the University of Pennsylvania.
Service Models
HS service
ASCT patients before July 2012 were admitted to an HS service. This service had a mix of transplant and nontransplant patients with hematological malignancies. Daytime staffing for the team included 1 attending, a board-certified specialist focused on hematological malignancies; 1 firstyear medical oncology fellow; 1 medical resident (second-or third-year resident in an internal medicine training program), and 2 interns (firstyear resident in an internal medicine training program). Nighttime coverage was provided by 1 medical resident and 1 intern. Attending physicians and HS rotated on 14-day cycles. Both the oncology fellow and the attending were available overnight for emergent patient issues. Because ASCT is a planned procedure, all patients were scheduled daytime weekday admissions.
APP service
Starting July 2012 ASCT patients were admitted to a newly developed APP service. The service was staffed with 1 attending, drawn from the same faculty group as those in the HS service, most with a clinical focus in ASCT. Between 7 a.m. and 7 p.m., Monday through Friday, coverage was provided by 2 APPs. One APP rotated onto the ASCT service every 3 months from a larger pool of oncology-specific APPs. The other APP was assigned exclusively to the ASCT service without rotating off to provide increased continuity of care. As on the HS service, attending physicians rotated on 14-day cycles and were available overnight for emergent issues. Nighttime and weekend coverage was provided by moonlighters who covered multiple oncology services. All moonlighters were employees of the University of Pennsylvania health system and consisted of licensed residents and fellows and occasionally oncology-specific APPs.
Data Sources and Data Elements
All data were abstracted from our inpatient and outpatient electronic medical records. Demographic data collected included age, sex, indication for transplantation, and type of graft donor: sibling, unrelated donor (10/10 or 9/10 match), or cord blood. Graft source was separated into peripheral blood, bone marrow, or cord. The type of conditioning regimen was identified as either myeloablative or reduced intensity. The pretransplant disease status for patients with acute myeloid leukemia (AML) and acute lymphoid Figure 1 . Consort diagram. leukemia was determined by the last bone marrow biopsy before ASCT. Laboratory values measured included WBC count, hemoglobin (Hb), platelet count, and serum creatinine. A hematopoietic cell transplantationespecific comorbidity index (HCT-CI) score was calculated for all patients [18] , and an Eastern Cooperative Oncology Group performance status (ECOG PS) [19] was obtained via chart review.
Outcomes
Primary outcomes were overall and relapse-free survival rates at 100 days post-transplant. Secondary outcomes included LOS, 14-and 30-day readmission rates, in-hospital death rate, rates of ICU transfers, and infectious complications such as pneumonia (PNA), urinary tract infections, bacteremia, and Clostridium difficile colitis. Episodes of PNA were measured by radiological evidence of infection in conjunction with chart review documentation of treatment. Microbiology data were used to assess for infectious complications. The ordering behavior of inpatient providers was measured by recording the number of blood cultures, urine cultures, and radiological films (chest x-rays, computed tomographies, and/or magnetic resonance images) ordered per patient by each service during the entirety of the hospitalization. Finally, we evaluated differences in hospital charges accrued during admission. Hospital charges included laboratory and radiological testing, nursing care, and the transplant itself. We did not take into account professional or physician billing, which is allocated separately.
Analysis
Primary and secondary analyses
In our primary analysis we compared patient, provider, and cost outcomes on both HS and APP services before and after the intervention date of July 2012. During our data collection, we identified a smaller subset (n ¼ 27) of ASCT patients who were admitted to the HS service from October 2012 to October 2013. These patients were assigned to the HS service due to capacity limitations on the APP service. We performed a secondary sensitivity analysis comparing this subset of patients with patients synchronously admitted to the APP service to control for potential calendar time differences ( Figure 2 ).
Statistical plan
Descriptive statistics were used to compare baseline characteristics between the 2 study populations. Categorical outcomes were compared between the HS and APP services using Fisher's exact test and chi-square tests. Continuous outcomes were compared using t-tests. We also used multivariable linear and logistic regression models adjusted for graft source and HCT-CI score to obtain mean effects and odds ratios, respectively, with corresponding confidence intervals. All tests were 2-sided, and a P < .05 was considered statistically significant. Analyses were performed using STATA version 13.0 software (StataCorp LP, College Station, TX, USA).
RESULTS
Primary Analysis (Pre/Post July 2012) Study population
Patient characteristics for both the primary and secondary analyses are listed in Table 1 . In the primary analysis, we evaluated 86 patients on the HS service and 81 patients on the APP service. There was no difference in the mean age or sex of the patients on the 2 services, and the leading indication for ASCT was AML. Among patients with acute leukemia there was no difference in the pretransplant disease status. Most donors in both groups were unrelated followed by sibling donors. Unrelated donors were further subdivided into 10/10 versus 9/10 donors, with no differences (P ¼ .62). The graft source differed between groups, with more patients on the HS service (28% versus 10%, P < .01) receiving bone marrow grafts compared with peripheral blood stem cells. Laboratory testing on the day of admission revealed similar results except for Hb, which was significantly higher on the APP service (11.2 g/dL versus 10.5 g/dL, P ¼ .02). There was no difference in the HCT-CI score among patients admitted for transplant, but there was a statistically significant difference in performance status, with more patients having a higher ECOG PS on the APP service (Table 1) .
Outcomes
Results of our comparative outcomes analysis are shown in Table 2 . Our primary outcomes, the 100-day survival rate (90% versus 90%, P ¼ .90) and relapse-free survival rate (78% versus 67%, P ¼ .14), were similar in both groups. Mean length of stay was 29.4 days on the APP service versus 32.1 days on the HS service (P ¼ .12). There was no difference in readmission rates at 14 or 30 days postdischarge (Table 2 ). There was a nonestatistically significant 6% decrease in deaths during the hospitalization favoring the APP service (P ¼ .13) and a 10% decrease in ICU transfers on the APP service (P ¼ .06). There were less cases of documented PNA on the APP service (15% versus 28%, P ¼ .04), but other infectious complications were comparable. With regards to provider ordering behavior, there were more blood culture orders per patient (6.7 versus 4.2, P ¼ .03) and a trend toward more radiological film orders per patient (7.8 versus 5.2, P ¼ .05) on the HS service. Mean hospital charges were not different between the 2 groups (P ¼ .66). Regression analyses adjusted for graft source and HCT-CI score were performed on the primary outcomes and other outcomes that reached near significance. These results were not different from unadjusted analyses (Table 3) .
Secondary Analysis (October 2012 to October 2013) Study population
In this secondary sensitivity analysis, we compared the 81 patients admitted to the APP service to the subset of 27 patients admitted to the HS service during the identical time period from October 2012 to October 2013. In this analysis, there were no differences in age, sex, underlying disease, donor type, graft source, disease status, or conditioning intensity (Table 1) . Admission characteristics were similar, except, as in the primary analysis, there was a statistically significant higher mean Hb on the APP service at admission (11.2 g/dL versus 10.1 g/dL, P ¼ .03). There was no difference in HCT-CI score or ECOG PS between the 2 groups.
Outcomes
In our secondary analysis, adjusted regression models were not used to evaluate outcomes because all relevant confounders were balanced between the 2 comparison groups. With respect to this sensitivity analysis, LOS was longer on the HS service (37.2 days versus 29.4 days, P ¼ .01) than on the APP service. There were no differences in rates of readmission, in-hospital death, ICU transfers, or infectious complications among the 2 provider groups ( Table 2 ). In terms of provider behavior, the HS service ordered more radiological films (8.1 versus 5.2, P ¼ .05) and blood cultures (9.3 versus 4.2, P < .01) than the APP service. Hospital charges were significantly higher on the HS service than on the APP service ($597,482 versus $465,501, P ¼ .04). Rates of 100-day survival (89% versus 90%, P ¼ 1.0) and relapse-free survival (78% versus 78%, P ¼ 1.0) were the same in both groups.
DISCUSSION
ASCT is a high-risk, costly procedure that offers the only chance of cure in some patients with hematological malignancies. Patients admitted for this procedure are generally hospitalized for 4 to 6 weeks and can have a hospital course complicated by infection, graft-versus-host disease, or organ failure [1] [2] [3] . Logistically, these patients have a complex discharge process, with most patients going home with central venous access and complicated medication regimens. In this study we evaluated outcomes of patients undergoing ASCT on a newly developed APP service and found this alternative model of care resulted in similar survival rates as those patients receiving care on a traditional HS service. This is the largest study evaluating patient outcomes by inpatient provider type in oncology and the first to look at outcomes of MDS indicates myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; BM, bone marrow; PB, peripheral blood; PLT, platelets; Cr, creatinine.
* This is the P value for the primary analysis (before/after the intervention date). It compares baseline characteristics of the APP service in the first column (shaded) to HS service in the second column.
y This is the P value for the secondary analysis (patients admitted during the same time period). It compares baseline characteristics of the APP service in the first column (shaded) to the HS service in the fourth column. z Values in parentheses represented standard deviation for continuous outcomes and percentage involved for categorical outcomes.
x Other diagnoses include myeloproliferative disorders, chronic myeloid leukemia, non-Hodgkin lymphomas, multiple myeloma, and aplastic anemia. k The pretransplant disease status was assessed only in patients with AML and ALL. { Unrelated donors were further subtyped into 10/10 vs. 9/10 match. # Statistically significant P < .05.
** Includes only patients with documented ECOG PS.
ASCT patients specifically. Unlike other patient populations, ASCT patients have a unique complexity yet are uniform in the timing and indication for admission. In our primary analysis, baseline characteristics revealed that these 2 services had comparable patient populations other than graft source. No major differences were seen in patient demographics, indication for transplant, or type of transplant performed. Although the ECOG PS suggested a higher acuity on the APP service, this information was incomplete because not all patients had documented scores. With regards to outcomes, we found no difference in 100-day survival or 100-day relapse-free survival rates, a standard time point for the assessment of ASCT patients. This was accomplished by the APP service with no increase in deaths during ASCT or change in readmission rates.
Additionally, there were significantly less episodes of PNA on the APP service as well as nonestatistically significant decreases in ICU transfers and LOS on the APP service. There were less blood cultures and a trend toward less radiological films ordered on APP service, suggesting that continuity of care in the APP model may lead to decreased utilization. To account for imbalances in graft source and HCT-CI score seen in our baseline characteristics, multivariable regression analyses were performed. Results of these analyses were consistent with our comparative analysis demonstrating increase odds of PNA on the HS service and increase in blood culture orders on the HS service with no difference in 100-day survival outcomes.
It can be hypothesized that an APP model, through development of provider expertise, creates an opportunity for the delivery of high-level, consistent care in this very unique patient population. Additionally, given the protocolized nature of ASCT, APPs have an inherent advantage of familiarity with the transplant process due to ongoing exposure. Finally, the similar 100-day patient outcomes may reflect the role of the attending physician, which remained constant in both service models. In our study, the newly developed APP service provided comparable quality care as indicated by outcomes, LOS, and similar rates of complications as patients treated by HS.
A unique feature of our study was our ability to compare outcomes before and after the intervention date in our primary analysis and concurrently in our secondary analysis. This latter analysis allowed us to compare a subset of ASCT patients admitted to the HS service with patients admitted to the APP service over the same time period, eliminating the effect of secular trends. This was demonstrated by our baseline patient characteristics that revealed a more equivalent patient population than in our primary analysis. In this secondary analysis, there was no difference in readmission rates, ICU transfers, or infectious complications. Interestingly, we found an increased LOS that was associated with increased test ordering and, consequently, an increase in mean hospital charges on the HS service. These outcomes support trends observed in our primary cohort. One explanation for the findings in this analysis is that limiting HS exposure to allogeneic transplant decreases familiarity with this patient population, resulting in longer hospitalizations and increased ordering behavior. Alternative explanations are that these patients differed in disease severity in ways that were nonmeasureable or that there was selection bias in patient triage. * Multivariable logistic and linear regression models for the primary analysis were performed adjusting for graft source and HCT-CI score.
y Statistically significant P < .05. * This is the P value for the primary analysis (before/after the intervention date). It compares outcomes of the APP service in the first column (shaded) to HS service in the second column.
y This is the P value for the secondary analysis (patients admitted during the same time period). It compares outcomes of the APP service in the first column (shaded) to the HS service in the fourth column. z Values in parentheses represented standard deviation for continuous outcomes and percentage involved for categorical outcomes.
x Statistically significant P < .05.
Our study adds to a growing body of literature that supports the role of APPs in clinical settings that have traditionally been filled by residents [13] [14] [15] [16] [17] . In a retrospective review of 2 ICUs staffed by APPs and HS, respectively, patients had similar mortality, LOS, and rates of discharge to skilled care facilities [15] . A previously published study conducted at the University of Pennsylvania evaluated the care of trauma patients admitted to an HS service compared with an APP service. Results of this analysis found no difference in ICU transfers or readmission rates with a trend toward decreased LOS in the APP group [16] . Within the practice of oncology, a study evaluating outcomes of patients admitted for reinduction chemotherapy for AML by provider type (HS versus APP) found no difference in mortality or ICU transfers but did describe decreased LOS and lower readmission rates on the APP service [17] .
Although we demonstrate similar 100-day outcomes, and possibly even benefits of implementation of a transplantspecific APP service, we must consider both the financial costs and potential educational loss to HS before widespread implementation of these novel care models. Although a complete cost analysis is beyond the scope of this study, it is of interest to consider that salaries of full-time APPs are double that of trainees, and in our practice model, there is the added costs of moonlighters for overnight coverage [20] . Furthermore, removal of HS from the care of ASCT patients may have a negative impact on the physician workforce prepared to treat these patients. Studies have predicted significant shortages in oncology and in bone marrow transplantation in particular, leading to calls for increased trainee engagement in transplantation as a means of improving recruitment into the field [8, 21] . There are also potential educational losses for residents and fellows in training as their roles are transitioned to APPs, although some studies have suggested that skilled APPs may add to the educational experience of HS [22, 23] . Our study suggests that limiting the exposure that HS have with ASCT may prolong the LOS and lead to increased hospital charges. Future research will need to be performed to determine if ASCT should remain a part of HS training.
There are several limitations of this study design. A retrospective cohort study limits data collection to that available in the clinical record. As a single-center study, there are restrictions to generalizability, but because most ASCTs are performed at academic centers [24], our findings can be applicable to many transplant centers who have or are considering implementation of APP services. Additionally, our primary analysis has inherent limitations due to unmeasurable changes that may have occurred with institutional practices over time. However, our primary findings are found to be robust when evaluated in a secondary analysis comparing concurrent groups of patients exposed to the HS and APP services, respectively. Our study is also restricted by sample size with limited power to detect a difference in 100-day survival rates. Notably, for our primary analysis 100-day survival outcome, post-hoc power calculations demonstrate that we would need 446 subjects in each arm to be 80% sure the upper limit of a 1-sided 95% confidence interval will exclude a difference in favor of the HS group of more than 5%. This sample size was not feasible given our study population, and we acknowledge the lack of an observed difference in 100-day survival rates may be a consequence of limited power. Finally, we did not separate the effect of moonlighters in this study but rather included them as part of the APP service model.
In conclusion, in the care of ASCT patients, a specialized service using APPs provided similar 100-day overall survival and relapse-free survival rates with potential benefits including decreased test ordering. In the setting of workhour regulations limiting HS resources, this study suggests that a service incorporating APPs is an acceptable model in the care of complex ASCT patients. As we use these models in the future, it will be important to consider the impact on patient outcomes, physician training and education, and the value of care provided.
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